BRCA-Associated Protein-1 (BAP1) Loss and Real-World Outcomes of Immune Checkpoint Inhibitor Therapy in Pleural Mesothelioma

被引：0
|
作者：
Smith, C. J. [1 ]
Desai, A. [1 ]
Hazim, A. [1 ]
Dimou, A. [1 ]
Leventakos, K. [1 ]
Molina, J. [1 ]
Parikh, K. [1 ]
Kommalapati, A. [1 ]
Hocum, C. [1 ]
Moffett, J. N. [1 ]
Schwecke, A. [1 ]
Mansfield, A. S. [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Mesothelioma; Immunotherapy; BAP1;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP14.04-01
引用
收藏
页码：S726 / S727
页数：2
相关论文
共 50 条
  • [21] Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis
    Huang, Richard S. P.
    Carbone, David P.
    Li, Gerald
    Schrock, Alexa
    Graf, Ryon P.
    Zhang, Liangliang
    Murugesan, Karthikeyan
    Ross, Jeffrey S.
    Tolba, Khaled
    Sands, Jacob
    Oxnard, Geoffrey R.
    Spigel, David
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (01)
  • [22] INCIDENCE AND RISK FACTORS FOR STROKE ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITOR THERAPY IN CANCER PATIENTS USING REAL-WORLD CLINICAL DATA
    Jain, Prantesh
    Gutierrez, Jahir
    Guha, Avirup
    Jain, Chhavi
    Patil, Nirav
    Shen, Tingke
    Stanevich, Ilya
    Mangla, Ankit
    De Lima, Marcos
    Barnholtz-Sloan, Jill
    Dowlati, Afshin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A384 - A385
  • [23] Phase II trial of the PARP inhibitor, niraparib, in BRCA1-Associated Protein 1 (BAP1) and other DNA damage response (DDR) pathway deficient neoplasms including cholangiocarcinoma.
    George, Thomas J.
    DeRemer, David L.
    Lee, Ji-Hyun
    Staal, Stephen
    Markham, Merry Jennifer
    Jones, Dennie V.
    Hosein, Peter Joel
    Daily, Karen Colleen
    Chatzkel, Jonathan Alexander
    Ramnaraign, Brian Hemendra
    Close, Julia Lee
    Murphy, Martina Cathryn
    Allegra, Carmen Joseph
    Rogers, Sherise C.
    Ali, Azka
    Hromas, Robert A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [24] Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor Era
    Hiroki Ishihara
    Yuki Nemoto
    Kazutaka Nakamura
    Hidekazu Tachibana
    Hironori Fukuda
    Kazuhiko Yoshida
    Hirohito Kobayashi
    Junpei Iizuka
    Hiroaki Shimmura
    Yasunobu Hashimoto
    Kazunari Tanabe
    Tsunenori Kondo
    Toshio Takagi
    Targeted Oncology, 2022, 17 : 307 - 319
  • [25] Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor Era
    Ishihara, Hiroki
    Nemoto, Yuki
    Nakamura, Kazutaka
    Tachibana, Hidekazu
    Fukuda, Hironori
    Yoshida, Kazuhiko
    Kobayashi, Hirohito
    Iizuka, Junpei
    Shimmura, Hiroaki
    Hashimoto, Yasunobu
    Tanabe, Kazunari
    Kondo, Tsunenori
    Takagi, Toshio
    TARGETED ONCOLOGY, 2022, 17 (03) : 307 - 319
  • [26] Patterns of immune checkpoint inhibitor utilization and PD-L1 testing in advanced gastroesophageal cancers using real-world data.
    Kaur, Jasmeet
    Zhang, Li
    Hasler, Jill S.
    Dotan, Efrat
    Cann, Christopher G.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 370 - 370
  • [27] Real-world outcomes in locally advanced or metastatic urothelial carcinoma following platinum and PD-1/L1 inhibitor therapy
    Hepp, Zsolt
    Shah, Sonali N.
    Liang, Shang-Ying
    Tan, Katherine
    Balakrishna, Shreya
    FUTURE ONCOLOGY, 2021, 17 (32) : 4343 - 4353
  • [28] Real-world outcomes of 18,186 metastatic solid tumor outpatients: Baseline blood cell counts correlate with survival after immune checkpoint inhibitor therapy
    Goldschmidt, Jerome H.
    Chou, Lin-Na
    Chan, Philip K.
    Chen, Liwei
    Robert, Nicholas
    Kinsey, Joyce
    Pitts, Katherine
    Nestor, Matt
    Rock, Edwin P.
    Lazarus, Hillard M.
    CANCER MEDICINE, 2023, 12 (22): : 20783 - 20797
  • [29] Outcomes of real-world (RW) patients (pts) with advanced NSCLC (aNSCLC) and high programmed cell death-ligand 1 (PD-L1) expression receiving first line (1L) immune checkpoint inhibitor (ICI) therapy
    Hsu, M. L.
    Ge, W.
    Wu, N.
    Quek, R.
    Liu, J.
    Jalbert, J. J.
    Rietschel, P.
    Feliciano, J.
    Harnett, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1056 - S1056
  • [30] Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice
    Richardson, Debra L.
    Quintanilha, Julia C. F.
    Danziger, Natalie
    Li, Gerald
    Sokol, Ethan
    Schrock, Alexa B.
    Ebot, Ericka
    Bhardwaj, Neeru
    Norris, Tanesha
    Afghahi, Anosheh
    Frachioni, Anthony
    Washington, Christina
    Dockery, Lauren
    Elvin, Julia
    Graf, Ryon P.
    Moore, Kathleen N.
    CLINICAL CANCER RESEARCH, 2024, 30 (20) : 4644 - 4653
12345